Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength
Rhea-AI Summary
Fosun International (FOSUF, FOSUY) has received three 2026 awards from Global Banking and Finance Review: ESG & Sustainability Awards – Best Sustainable Development Company Asia, CSR Awards – Best CSR Company Asia, and Brand of the Year Awards – Holding Group Brand of the Year Asia.
According to Fosun International, its MSCI ESG rating was raised to AAA in 2026, its FTSE Russell ESG score reached 4.2/5 with continued FTSE4Good inclusion, and it ranked top 1% in S&P Global Sustainability Yearbook (China Edition). Fosun Foundation reports its Rural Doctors Program has supported 25,000 rural doctors and benefited 3 million rural families, while AI Rural Doctor Assistant 2.0 and other AI initiatives and healthcare products from group companies such as Henlius, Fosun Pharma and Fosun Tourism Group are expanding their impact globally.
Positive
- MSCI ESG rating upgraded to AAA in 2026 after five years of effort
- FTSE Russell ESG score of 4.2 out of 5 with FTSE4Good inclusion
- Ranked top 1% in S&P Global Sustainability Yearbook (China Edition) for three years
- Rural Doctors Program supported 25,000 rural doctors and 3 million rural families
- AI Rural Doctor Assistant deployed to 25,000 rural doctors with 92% satisfaction rate
- Artesunate for injection has treated more than 88 million severe malaria patients globally
- HANSIZHUANG approved in over 40 countries and regions for ES-SCLC first-line treatment
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fosun International received the "ESG & Sustainability Awards – Best Sustainable Development Company Asia 2026", "CSR Awards – Best CSR Company Asia 2026", and "Brand of the Year Awards – Holding Group Brand of the Year Asia 2026". These accolades underscore the progress it has made in executing its sustainable development strategy, strengthening corporate governance, fulfilling its social responsibility and advancing environmental protection, while also affirming its long‑standing commitment to transparent operations and proactive stakeholder communication.
Global Banking and Finance Review highlighted that Fosun's recognition in these awards reflects its balanced development and outstanding performance across multiple areas. On the business front, Fosun has continued to optimize its global industrial ecosystem, delivering resilient growth in its core businesses and strengthening its ability to navigate economic cycles. On the sustainability front, the company has integrated ESG principles into both strategic decision-making and day-to-day operations, underpinned by a clear roadmap and strong execution. The judging panel particularly emphasized that Fosun's efforts to align commercial value with social value offer a valuable reference for companies in
Outstanding ESG Performance and Continued Advancement of Sustainable Development Strategy
Fosun has embedded sustainable development at the heart of its corporate strategy and introduced the "Create IMPACT" sustainable development strategy, which sets out six long-term directions: Innovation-Driven, Mindful Operation, People and Partner Oriented, Advanced Governance, Climate and Planet Positive, and Transparency. In 2026, Fosun achieved a comprehensive breakthrough in Environmental, Social, and Governance (ESG) performance. Its MSCI ESG rating has been upgraded to the highest rating AAA, marking a significant milestone after five years of sustained effort since first receiving an AA rating in 2021 and indicating that its overall management standards have reached a leading position among global peers. Meanwhile, Fosun's FTSE Russell ESG score rose to 4.2 (maximum score: 5) and has been included in the FTSE4Good Index Series for the fifth consecutive time, maintaining a leading position in the rating systems of internationally recognized index providers.
Fosun has also achieved steady improvement in mainstream international sustainability assessments. It has been included in S&P Global's Sustainability Yearbook 2026 and, for the third consecutive year, ranked among the top
Fosun for Good, Actively Giving Back to Society
As a responsible corporate citizen, Fosun established Fosun Foundation in 2012, continuously creating social value in areas such as global emergency relief, rural revitalization, healthcare, and education and culture.
Fosun has continued to deepen its commitment to rural revitalization and primary healthcare. Since its launch in 2017, the Rural Doctors Program has supported 25,000 rural doctors and benefited 3 million rural families. The program was also selected as one of the UN Global Compact's "20 Cases of Private Sector's Sustainable Development in
In the face of sudden disaster, Fosun Foundation has demonstrated its efficient response capability. In July 2026,
Fosun has also continued to support youth entrepreneurship and global innovation. The 8th edition of the "Protechting Open Innovation Program" jointly launched by Fosun Foundation, Fidelidade, and Luz Saúde, reached new heights this year. Focused on cutting-edge areas such as insurtech, medtech, artificial intelligence (AI), and ESG, the program received 637 applications from more than 50 countries and regions, setting a new record. In addition, the program provided deep incubation support, including over 80 mentor sessions and corporate immersion days for shortlisted teams. It also served as a bridge connecting
Innovation-Driven Growth, Bringing AI and Healthcare Benefits to the Public
Fosun has consistently prioritized solving real-world problems and has deeply integrated AI into its core businesses, including pharmaceuticals, healthcare and intelligent services. On the research and development (R&D) front, Henlius' AI-powered protein drug design platform has increased the binding affinity of a core project molecule by more than 20 times in just three months, significantly accelerating the development of new drugs. On the service front, Fosun Tourism Group has launched the AI G.O intelligent system, transforming decades of non-standard service experience into a 24/7 digital asset to deliver more personalized and thoughtful experiences for guests. Fosun has also been actively advancing technology for social good. Its "AI Rural Doctor Assistant" has been rolled out to 25,000 rural doctors, with a user satisfaction rate of
Fosun's Health business remains committed to bringing new hope of cure to more patients. It has established a deep presence in core therapeutic areas such as oncology, immunology and inflammation, and neurodegenerative diseases, while actively expanding into cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, it continues to consolidate its core technical platforms including antibodies, antibody-drug conjugates (ADCs), small molecules and cell therapies, while expanding into cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. It has achieved a series of breakthroughs that are benefiting patients worldwide. As the world's first monoclonal antibody targeting PD-1 approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), HANSIZHUANG has been approved for marketing in over 40 countries and regions. HLX43 has shown significant advantages, with a favorable efficacy and safety profile in non-small cell lung cancer (NSCLC), gynecological tumors, and other indications. HLX22 is the world's first anti-HER2-targeted therapy to receive Orphan Drug Designation (ODD) approvals from both the US Food and Drug Administration (FDA) and the European Commission (EC) for gastric cancer.
At the same time, Fosun Pharma is committed to enhancing medication accessibility and contributing to the global vision of a "malaria-free world". As of the end of 2025, Fosun Pharma's independently developed artesunate for injection had saved more than 88 million patients with severe malaria worldwide, with more than 440 million vials supplied globally.
Looking ahead, Fosun will continue to deepen its "Create IMPACT" sustainable development strategy, actively taking on greater social responsibility through innovation and responsible operations, and endeavoring to build a more responsible, inclusive, and sustainable future.
View original content:SOURCE Fosun